Post-earnings recap
Reported
Wed, May 13, 2026
EPS actual
$-0.32
EPS est.
$-0.32
EPS surprise
-0.95%
1-day move
+8.55%
Tango Therapeutics reported a wider-than-expected loss per share, which may raise concerns among investors. However, the stock reacted positively, increasing by 8.55%. This rise could be attributed to other factors not reflected in the earnings metrics, such as market sentiment or potential future developments.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.32 | $-0.31 | -0.95% |
| Revenue | $— | $1M | — |
No transcript is on record for the earnings call, so the analysis is based solely on the numerical results.
Tango Therapeutics, Inc. is a biotechnology company focused on developing targeted therapies for cancer treatment. Operating in the health care sector, its innovative approach aims to improve patient outcomes through precision medicine, making it a key player in the ongoing fight against cancer.
Last quarter
In Q4-2025, Tango reported an EPS of $-0.29, slightly better than the expected $-0.31, which led to a positive stock reaction of 36.28% the following day. However, revenue details were not disclosed, leaving some uncertainty about overall performance.
EPS beat streak
0Q
EPS beat rate
50%
Avg EPS surprise
+111.81%
Avg 1-day reaction
+1.99%
Analysts expect Tango to report a loss this quarter, with a consensus EPS of $-0.31 and revenue around $1M. The market is looking for signs of improvement in both metrics compared to previous quarters.
Bull case
If Tango can beat the EPS estimate and show stronger revenue growth, it could signal that its therapies are gaining traction, potentially leading to a positive stock reaction.
Bear case
Conversely, if the company misses on EPS and revenue, it may raise concerns about its financial health and ability to fund future projects, which could negatively impact the stock.
Key metrics to watch
EPS
$-0.31Earnings per share (EPS) is a critical measure of profitability, and investors will be keen to see if Tango can narrow its losses this quarter.
Revenue
$1MRevenue figures will indicate the company's ability to generate sales and support its ongoing research and development efforts.
The print will turn on these.
Q1
Will Tango report an EPS better than the consensus estimate of $-0.31?
A beat on EPS could indicate improving operational efficiency and investor confidence, which is critical for a biotech firm.
Q2
What revenue figure will Tango report, and how does it compare to the expected $1M?
Revenue performance will be crucial for assessing the company's market traction and financial sustainability.
—
Est. EPS
—
Est. Rev
—
Impl. Move
±3.4%
Why consensus could be wrong
The consensus may underestimate Tango's potential for revenue growth, as recent developments in their pipeline could lead to unexpected sales.
Supporting evidence
The company has a history of beating EPS estimates, which could indicate stronger operational performance than expected.
The options market is pricing a significant move, suggesting that traders anticipate a surprise in either direction.
Key risk
If revenue comes in significantly above $1M, it could challenge the current bearish sentiment.
Pre-commit to what would confirm each case.
This quarter's results will be pivotal in determining whether Tango can maintain investor confidence amid ongoing losses.
Bull confirmed if
An EPS of better than $-0.28 and revenue exceeding $1M would confirm a bullish outlook.
Bear confirmed if
An EPS worse than $-0.38 and revenue below $1M would support a bearish perspective.
What the market is pricing for the move.
Implied Move
±20.32%
Historical Avg
±14.2%
The options market is pricing in a significant move of over 20%, suggesting that investors expect volatility around the earnings announcement.
Options are pricing ±20.3% while TNGX has averaged ±14.2% over the last 8 prints — setup is pricing rich.
ATM IV
2.8%
30d HV
81.5%
Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.
Bought
$0.00
0 sh
0 insiders
Sold
$660,796.08
27,000 sh
1 insider
Net
$660,796.08
Net selling
Most Active Insiders· 2 open-market trades
$660,796.08
Net selling
Smart-money positioning from the most recent 13F filings.
Institutional
128.50%
of float
Insider
1.19%
of float
Holders
338
institutions
Top Holders· as of Jun 2026
RTW Investments LP
13,900,620 sh · $303.5M
8.24%
4.5%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Tango beats expectations, history suggests the stock could rise by an average of 0.09%, confirming a positive outlook.
In line / cautious
If results are in line with expectations, the stock may see a muted response as investors await clearer guidance.
Miss
A miss could lead to a decline, with historical data indicating an average drop of 3.08% in similar situations.
The lines on the call that would change the story.
Recent Transactions
Oct 1, 2026 · @ $24.45
26,400 sh
$645,604.08
Oct 1, 2026 · @ $25.32
600 sh
$15,192.00
Open-market trades only (Form 4 codes P/S). Awards, exercises, and tax-withholding excluded as routine compensation noise.
Blackrock Inc.
12,438,444 sh · $271.5M
7.38%
42.2%
FMR, LLC
12,333,339 sh · $269.2M
7.31%
24.5%
Farallon Capital Management LLC
12,277,000 sh · $268.0M
7.28%
34.9%
Boxer Capital Management, LLC
10,876,219 sh · $237.4M
6.45%
Flat
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.